Good morning :)
$
₹
TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc.

TLSI

NASDAQ
Asset Logo

TriSalus Life Sciences Inc.

TLSI

NASDAQ
$3.620.91% (+0.03)
$
₹
$3.620.91% (+0.03)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $221.1M the stock is ranked 4116

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

47.00
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.22
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-62.59%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+189.69%

Earnings Growth

+77.7%

Rev. Growth

+17.65%

See Detailed Forecast

Company Profile

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 189.69% growth, versus a trailing 3-year CAGR of -10.84%.

2026
Current$3.59Baseline
Analyst Target - 1 year
Target$10.4+189.69%

All values in $

202220232024202520262027$5.28$7.34$9.39Target+189.69%
2026
Current$3.59Baseline
Analyst Target - 1 year
Target$10.4+189.69%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 17.65% growth, versus a trailing 3-year CAGR of 53.85%.

2025
Current$45.15Baseline
Forecast for Dec 2026
High$55.52+22.97%
Average$53.11+17.65%
Low$49.1+8.75%

All values in $ Million

2021202220232024202520268.4012.3918.5129.4345.15Low+8.75%Average+17.65%High+22.97%
2025
Current$45.15Baseline
Forecast for Dec 2026
High$55.52+22.97%
Average$53.11+17.65%
Low$49.1+8.75%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.48Baseline
Forecast for Dec 2026
High$-0.27+81.76%
Average$-0.33+77.7%
Low$-0.39+73.65%

All values in $

2021202220232024202520260.150.18-1.87-1.61-1.48Low+73.65%Average+77.7%High+81.76%
2025
Current$-1.48Baseline
Forecast for Dec 2026
High$-0.27+81.76%
Average$-0.33+77.7%
Low$-0.39+73.65%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

11.5
-10.8
13.2
-9.7
8.8
1.5
11.4
-9.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue6.457.367.348.269.1611.2111.5613.208.8911.40
Net Income-13.21-4.33-2.39-10.10-10.37-8.28-10.81-9.751.53-9.18
Net Profit Margin-204.72%-58.82%-32.64%-122.35%-113.17%-73.91%-93.47%-73.85%17.29%-80.53%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
TriSalus Life Sciences Inc. -47.00-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare TLSI with any stock or ETF
Compare TLSI with any stock or ETF
Comparing from
TLSI
ABT
DHR
Loading...

Frequently asked questions

  1. TriSalus Life Sciences Inc. (TLSI) share price today is $3.62 as of October 27, 2026 at 12:53 AM IST. The stock touched a day high of $3.77 and a day low of $3.50.

  2. TriSalus Life Sciences Inc. stock trades on NASDAQ under the ticker symbol TLSI.

  3. TriSalus Life Sciences Inc.'s market capitalization is $221.05M as of October 27, 2026 at 12:53 AM IST.

  4. TriSalus Life Sciences Inc.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. TriSalus Life Sciences Inc.'s price-to-book (P/B) ratio is 47.00 as of October 26, 2026.

  6. Yes, You can buy TriSalus Life Sciences Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy TriSalus Life Sciences Inc. shares in three steps: 1. Search TriSalus Life Sciences Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since TriSalus Life Sciences Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in TriSalus Life Sciences Inc. (TLSI) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.7601 shares at the current price of $3.62.

Loading...